ANDA Litigation Settlements

Spring 2014

GENERICally Speaking: A Hatch Waxman Litigation Bulletin
Case Name Drug Patent No(s). Publicly Available Terms

Merck Sharp & Dohme Corp. Aurobindo Pharma. Ltd., 13-5442 (D.N.J.)

Sustiva® (efavirenz)

6,639,071
6,673,372
6,939,964

N/A

Noven Pharma. v. Watson Labs. Inc., 11-5997 (D.N.J.)

Daytrana® (methylphenidate transdermal system)

6,348,211

Noven will grant Shire PLC a nonexclusive, royalty-bearing license to market generic methylphenidate transdermal patches beginning in September 2015, or earlier under certain unspecified conditions.


Related Publications

Fourth Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
December 29, 2023
Corcept Therapeutics, Inc. v. Teva Pharms. USA, Inc.
GENERICally Speaking Hatch Waxman Bulletin
December 13, 2023
Acadia Pharms. Inc. v. Aurobindo Pharma Ltd.
GENERICally Speaking Hatch Waxman Bulletin
December 7, 2023
H. Lundbeck A/S v. Lupin Ltd.
GENERICally Speaking Hatch Waxman Bulletin
November 7, 2023
Eisai R&D Mgmt. Co., Ltd. v. Dr Reddy’s Labs., Inc.
GENERICally Speaking Hatch Waxman Bulletin
Back to Top